---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-084938"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:18:13.615226+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics reports Q3 2023 net loss of $17.5M; highlights IND clearance for briquilimab in CSU

## Summary
- Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.
- Cash and cash equivalents of $103.9M as of Sept 30, 2023.
- FDA cleared IND for Phase 1b/2a study of subcutaneous briquilimab in CSU; first patient expected by end of 2023.
- Stanford-sponsored Phase 1/2 study in Fanconi Anemia: all 3 patients achieved full donor engraftment.
- Appointed Thomas Wiggans as Chairperson and Herb Cross as CFO.

## SEC filing metadata
- accession: 0001213900-23-084938
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/0001213900-23-084938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/ea187963-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-084938
- JSON: https://secwatch.observer/filing/0001213900-23-084938.json
- Plain text: https://secwatch.observer/filing/0001213900-23-084938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.